Symbicort Dosing and Administration
For asthma in patients ≥12 years: Start with 2 inhalations of Symbicort 80/4.5 mcg or 160/4.5 mcg twice daily based on asthma severity; for children 6-11 years: use only 80/4.5 mcg, 2 inhalations twice daily. For COPD: use 160/4.5 mcg, 2 inhalations twice daily. 1
Asthma Dosing
Adults and Adolescents (≥12 years)
- Symbicort 80/4.5 mcg: 2 inhalations twice daily for mild-to-moderate persistent asthma
- Symbicort 160/4.5 mcg: 2 inhalations twice daily for moderate-to-severe persistent asthma
- Dosing is based on pre-treatment asthma severity 1
Children (6 to <12 years)
- Symbicort 80/4.5 mcg only: 2 inhalations twice daily
- The higher strength (160/4.5 mcg) is not approved for this age group 1
Critical Safety Point: Symbicort must NEVER be used as monotherapy for asthma. Long-acting β2-agonists (LABAs) like formoterol increase the risk of serious asthma-related events when used alone 2. The combination with an inhaled corticosteroid (budesonide) is essential for safe use.
COPD Dosing
- Symbicort 160/4.5 mcg: 2 inhalations twice daily for maintenance treatment
- This is the only approved strength for COPD 1
- Used to reduce exacerbations and maintain airflow in patients with chronic bronchitis and/or emphysema
Administration Instructions
Route: Oral inhalation only via metered-dose inhaler (MDI) 1
Key administration points:
- Administer twice daily (approximately 12 hours apart)
- Rinse mouth with water after each use WITHOUT swallowing to reduce risk of oral candidiasis 1
- Not for relief of acute bronchospasm—patients need a separate short-acting β2-agonist (SABA) for rescue 1
Clinical Context and Evidence
The combination of budesonide (ICS) with formoterol (LABA) addresses both the inflammatory and bronchodilatory components of disease. For asthma, adding a LABA to ICS is the preferred adjunctive therapy for patients ≥12 years with moderate-to-severe persistent asthma (step 3 care or higher) 2. This combination improves lung function, reduces symptoms, and decreases exacerbations more effectively than increasing ICS dose alone 3.
The FACET study demonstrated that budesonide/formoterol reduced mild and severe exacerbations by 40% and 29% respectively, even at lower ICS doses (200 mcg daily), supporting earlier introduction of combination therapy 4.
For COPD, combination ICS/LABA therapy reduces exacerbation rates compared to LABA monotherapy, though with a 4% increased pneumonia risk 5. The 2023 Canadian guidelines recommend LAMA/LABA as first-line for most COPD patients, reserving ICS/LABA combinations for those with concomitant asthma features 6.
Important Limitations and Warnings
- Not for acute symptoms: Symbicort is maintenance therapy only; deteriorating asthma or COPD requires immediate medical attention 1
- Do not combine with other LABAs: Risk of overdose 1
- Monitor for: Oral candidiasis, pneumonia (especially in COPD), paradoxical bronchospasm, cardiovascular effects, and growth suppression in children 1
- Systemic corticosteroid effects: May occur with high doses or in susceptible individuals; taper slowly if transitioning from oral steroids 1